KetaVault™​

KetaVault™ is a world-first portal offering pharmaceutical and biotech companies, academic and clinical researchers, and government agencies direct access to PharmaTher's comprehensive proprietary data on ketamine. KetaVault™ is strategically designed to streamline and accelerate clinical trials, regulatory submissions, and commercialization initiatives for ketamine-based therapies.
KetaVault™ underscores PharmaTher’s leadership in the ketamine space, fostering high-value partnerships that could drive revenue growth and expand market opportunities.

KetaVault™: A Gateway to Expedited Ketamine Development

KetaVault™ provides partners with a significant competitive advantage by offering insights derived from years of dedicated research. This can directly support:
  • Expedited Regulatory Pathways: Leverage existing data to potentially streamline new drug applications and emergency use authorizations.
  • De-risked Clinical Development: Inform trial design and identify promising indications based on robust existing research.
  • Enhanced Commercial Strategy: Gain insights into manufacturing, control, and product development for market readiness.

Key Proprietary Information Available in KetaVault™ Includes:
  • Regulatory Filings: Investigational New Drug (IND) Applications.
  • Comprehensive Drug Information: Investigator’s Brochures.
  • Manufacturing Insights: Chemistry, Manufacturing, and Control (CMC) data.
  • Clinical Research & Data: In-depth clinical study protocols and research data for indications including Parkinson’s disease.
  • Orphan Drug Designations: Access to information supporting FDA Orphan Drug Approvals for Amyotrophic Lateral Sclerosis, Rett Syndrome, Complex Regional Pain Syndrome, Status Epilepticus, and ischemia/reperfusion injury during solid organ transplantation.
  • Novel Delivery Systems: Product development programs and regulatory filings for PharmaTher's ketamine microneedle patch and subcutaneous wearable pump.

Beyond Data: Comprehensive Partnership Support
​
In addition to data access, PharmaTher offers to support partners' clinical and commercialization initiatives with a reliable supply of ketamine, manufactured in the USA under the FDA’s stringent cGMP guidelines. This integrated offering positions PharmaTher as an end-to-end partner in the rapidly growing ketamine market.

    Interested in partnering?

Connect With Us

PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1